Vittoria Biotherapeutics, Inc. has announced the launch of its Phase 1 clinical trial for VIPER-101, a cutting-edge ...

Vittoria Biotherapeutics, Inc, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases, announced that in November, the first ...

The open-label Phase 1 study is designed to assess safety and preliminary efficacy, and to determine the recommended Phase 2 dose (RP2D) of VIPER-101 in patients with r/r CD5 positive nodal T cell ...

a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases, today announced that in November, the first patient was dosed in its ...

Morningstar brands and products Company Portfolio ...